Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s progress and financial results for the first half of 2024. Leire highlighted Genflow’s unique financial strategy, focusing on R&D while minimising operational costs. He emphasised Genflow’s success in advancing five key longevity programs, including the MASH liver program and research into Werner syndrome using synthetic organoids.
In addition, Leire revealed that Genflow successfully raised non-dilutive grant funding and brought institutional investors onto it share register, a crucial step after the company’s IPO during the pandemic. It also continues to push forward with clinical trials, including a promising dog study aimed at improving pet health and lifespan.
Looking ahead, the company is set to achieve critical milestones, including progressing to clinical trials and refining its discussions with regulatory agencies.
Visit Proactive’s YouTube channel for more interviews, and don’t forget to like the video, subscribe, and hit the notification bell for future updates.
#GenflowBiosciences #LongevityResearch #GeneTherapy #BiotechInvesting #ClinicalTrials #NonDilutiveFunding #WernerSyndrome #Sarcopenia #Healthspan #CEOInterview
#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews